Blueprint Medicines price target raised to $130 from $125 at Oppenheimer

Oppenheimer analyst Matthew Biegler raised the firm’s price target on Blueprint Medicines to $130 from $125 and keeps an Outperform rating on the shares post the Q2 report. The shares are mixed today despite strong Q2 Ayvakit sales, as the Street digested revised forward guidance numbers that at the lower bound imply decreasing sales, the analyst tells investors in a research note. “We partly believe management is being conservative with the guide – because that isn’t a new phenomenon,” the firm says. However, Opco acknowledges seasonal impacts “could slow things down” in the second half of 2025, and that sustained 25%-30% growth “may be unrealistic for a rare disease launch.”